AbbVie Inc., Amgen Europe GmbH (A Subsidiary of Amgen Inc.), and Biogen are Dominating the Global Adalimumab Market in 2019

Global Adalimumab Market is expected to grow with the CAGR of 4.8% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-adalimumab-market

Global adalimumab market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario. 

The major players dealing in global adalimumab market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In May 2019, AbbVie Inc. resolved the litigation with Boehringer Ingelheim (BI) for Humira. As per the agreement the Boehringer Ingelheim (BI) will be granted with the non-exclusive agreement for Humira. This patent resolution helped the company to expand its market across North America region.

AbbVie Inc. is the dominating player in global adalimumab market. The other key players existing in the market are Amgen (Europe) GmbH (A Subsidiary of Amgen Inc.), CELLTRION INC., Samsung Bioepis (a subsidiary of Samsung Biologics), Biogen, Coherus BioSciences, Innovent Biologics, Inc., Mylan N.V., Zydus Cadila, Hetero Biopharma Ltd., Fresenius Kabi Deutschland GmbH (A Subsidiary of Fresenius Kabi AG), Sandoz International GmbH (A Subsidiary of Sandoz (A Division of Novartis AG)), Pfizer Inc., Boehringer Ingelheim International GmbH among others.

Adalimumab MarketAbbVie Inc.

AbbVie Inc., headquartered in Illinois, U.S., founded in the year 2013. The company is a research- driven biopharmaceutical company having a great focus on treating diseases in order to make a remarkable impact on people's lives. The company has three business segments including immunology, hematologic oncology, HCV, other key products, in these immunology is the market focused segment. The company has wide products AndroGel (Testosterone Gel), CREON (Pancrelipase) Delayed-Release Capsules, DUOPA (Carbidopa/Levodopa Enteral Suspension), HUMIRA (Adalimumab), LUPRON DEPOT (leuprolide Acetate for Depot Suspension) URO, NORVIR Tablets (Ritonavir Tablets/Oral Solution) among others in which HUMIRA (Adalimumab) is the market focused category.

For instance,

  • In January 2018, AbbVie Inc. updated the HUMIRA (adalimumab) formulation by removal of citrate buffer that was responsible for causing pain while drug administration to paediatric patients. This initiative enhanced the company’s product access to wide population which in turn boosted the company’s revenue.

The company has wide presence across Africa, Asia-Pacific, Europe, Latin America, Middle East, North America, and South America. The company also has various subsidiary companies such as Knoll Pharmaceutical Company (New Jersey), AbbVie S.A. (Argentina), AbbVie Pty Ltd (Australia), AbbVie SA (Belgium) and AbbVie SAS(Colombia) among others.

Amgen Europe GmbH (A Subsidiary of Amgen Inc.)

Amgen Europe GmbH (A Subsidiary of Amgen Inc.) headquartered in Rotkreuz, Switzerland. The company is focused on developing and supplying innovator biologics dedicated to serving every patient every time. The company is engaged in manufacturing of AMJEVITA, which is the market focused product. The company has presence across Europe.

For instance,

  • In October 2018, Amgen launched AMGEVITA across the European region. This is the first biosimilar drug that has received European approval for treatment of inflammatory diseases. This product launch thus boosted the company’s product portfolio and allowed it to penetrate its root in adalimumab market.

Biogen

Biogen headquartered in Massachusetts, U.S., founded in the year 1978. The company is focused on developing innovative products in order to defeat the devastating neurological diseases. The company has two product categories marketed therapies, partnered therapies in which marketed therapies is the market focused category.

  • In October 2018, Biogen launched IMRALDI a biosimilar of Humira in European union. This product has indicated for treatment of adolescent hidradenitis suppurativa, crohn’s disease, paediatric plaque psoriasis, arthritis among several others. This initiative enhanced the company’s product portfolio and allowed it to earn more revenue.

The company has presence across Americas, Europe, and Asia-Pacific. The company also has various subsidiary companies Biogen Idec International GmbH (Switzerland), Biogen Idec (Argentina) SRL (Argentina), Biogen Idec Biotech India Pvt. Ltd (India), Biogen Idec Belgium N.V. (Belgium) and Biogen Idec Australia PTY Ltd (Australia) among others.